Biotin molecules could be used as suitable targeting moieties in targeted drug delivery systems against
tumors. To develop a
biotin targeted drug delivery system, we employed
human serum albumin (HSA) as a carrier.
Methotrexate (MTX) molecules were conjugated to HSA.
MTX-HSA nanoparticles (
MTX-HSA NPs) were prepared from these conjugates by cross-linking the HSA molecules.
Biotin molecules were then conjugated on the surface of
MTX-HSA NPs. The anticancer efficacy of
biotin targeted
MTX-HSA NPs was evaluated in mice bearing 4T1
breast carcinoma. A single dose of
biotin targeted
MTX-HSA NPs showed stronger in vivo antitumor activity than non-targeted
MTX-HSA NPs and free MTX. By 7 days
after treatment, average
tumor volume in the
biotin targeted
MTX-HSA NPs-treated group decreased to 17.6% of the initial
tumor volume when the number of attached
biotin molecules on
MTX-HSA-NPs was the highest. Average
tumor volume in non-targeted
MTX-HSA NPs-treated mice grew rapidly and reached 250.7% of the initial
tumor volume.
Biotin targeted
MTX-HSA NPs increased the survival of
tumor-bearing mice to 47.5 ± 0.71 days and increased their life span up to 216.7%. Mice treated with
biotin targeted
MTX-HSA NPs showed slight
body weight loss (8%) 21 days
after treatment, whereas non-targeted
MTX-HSA NPs treatment at the same dose caused a
body weight loss of 27.05% ± 3.1%.